I am a Machine Learning Specialist in the Raj Lab. My research interests include the modeling of Alzheimer’s Disease, Brain Segmentation, Parcellation, and other applied Deep Learning methods in Neuroscience. My most recent project is concentrated on predicting the cognitive ability using subjects’ T1-weighted MRI scans from the ADNI dataset. My other work focuses on computational and graph theoretical modeling of the brain, using neuroimaging technologies combined with machine learning modeling. Google Scholar:https://scholar.google.com/citations?user=N1TIix0AAAAJ

With my statistical and quantitative training backgrounds, I have multiple years of research experiences at the apolipoprotein (APOE) loci under the scopes of both epigenetics and genetics. I was the first to report the DNA methylation patterns at APOE loci in human primary peripheral CD4+ T cells across >900 free living human subjects, which was recently replicated by an independent UK biobank group. In addition, I have added some novel insights into the link between APOE and Alzheimer's disease (AD). Using the genome-wide association approach, I have identified 22 novel loci contributing to the risk of AD dementia stratified by APOE ε4 genotypes based on the whole exome sequencing data of the Alzheimer's disease sequencing project (ADSP). Based on the quantitative analysis of the DNA methylome and transcriptome of the primary human brain cortical tissues across multiple independent cohorts, I have found a potential factor to attenuate the risk effect of APOE ε4 on AD (under peer-review). For AD, APOE loci is considered as a high potency candidate for drug development where I am planning to fulfill my training packages for this effort.

Maria L. Maccecchini, PhD Founder, President & CEO, Annovis Bio, Inc. Maria Maccecchini founded Annovis Bio, Inc. to develop treatments for neurodegenerative diseases, such as Alzheimer’s (AD), Parkinson’s disease (PD) by normalizing the chemistry. The company is developing three classes of drugs for the treatment of neurodegeneration. The lead compound targets chronic conditions like AD and PD and is in phase 3 for early PD and in phase 2/3 for moderate AD. This lead compound is expected to stop the progression of the diseases. The second medicine targets acute conditions, like Traumatic Brain Injury and Stroke and the third is in phase 1 is for advanced AD. She started her first biotech company—Symphony Pharmaceuticals – to protect nerve cells from dying in stroke. After acquiring a Scottish and a Japanese company, Symphony later changed its name to Annovis. The company was acquired by Transgenomic Inc. in 2001. Before that she was General Manager of Bachem Bioscience, the US subsidiary of Bachem AG, Switzerland and Head Molecular Biology at Mallinckrodt; Dr. Maccecchini did one postdoc at Caltech and one at the Roche Institute of Immunology, her PhD in biochemistry is from the Biocenter of Basel with a 2-year visiting fellowship at The Rockefeller University.

Medical Doctor graduated from the Federal University of Minas Gerais, Brazil. Current MSc at the Integrated Program of Neuroscience at McGill University. I joined the Translational Neuroimaging Laboratory in 2022, where I work under the supervision of Dr. Pedro Rosa-Neto. My main research interests are the clinical correlations of Alzheimer's disease biomarkers, with a special focus on tau-PET imaging and other tau biomarkers.

Luiza Machado did her Master's at Universidade Federal do Rio Grande do Sul (Brazil) in Dr. Eduardo Zimmer's group. She is about to start her PhD under the supervision of Professor Henrik Zetterberg and Dr. Nicholas Ashton at the University of Gothenburg (Sweden). Her research focuses on the role of the glial cells in the etiology of Alzheimer's disease using neuroimaging and fluid biomarkers.

Dr. Tamiko R. MaGee-Rodgers joined the Global Alzheimer’s Platform Foundation (GAP) as Associate Director, Recruitment and Strategic Initiatives in March 2021 to lead GAP’s initiative to improve recruitment of underrepresented populations in AD clinical trials. She led efforts to launch GAP’s Inclusive Research Initiative in February 2022. Tamiko has worked in the field of aging for more than 18 years including roles as a Mental Health Clinician, Clinical Research Coordinator in Alzheimer’s disease studies and Staff Clinical Research Scientist supporting clinical research trials in total hip and knee arthroplasty. Tamiko’s clinical research experience has resulted in several journal publications and conference presentations and posters. Her most recent work is the publication of her dissertation entitled, “The Character Strengths of Nursing Home Administrators Who Lead Exemplary Long-Term Care Facilities.” Tamiko holds a Bachelor of Science degree in psychology from Indiana University- Bloomington, a Master of Science degree in gerontology from the University of Indianapolis, a graduate certificate in health policy, and a Doctor of Philosophy in organizational leadership from Indiana Wesleyan University where she currently serves as an adjunct faculty in Leadership studies.

Etienne Maheux (MSc) is a young scientist in applied mathematics and biostatistics. He has been working for about three years in the ARAMIS lab (https://www.aramislab.fr/) at the Paris Brain Institute under the supervision of Stanley Durrleman (PhD). Their research lies at the intersection of statistical learning and differential geometry with applications in neuroscience and clinical trial designs. In particular, they expand on a technique named "disease course mapping" for the analysis of longitudinal data, e.g. repeated data of the same subjects over time. This technique allows the construction of personalized models of disease progression for several neurodegenerative diseases: Alzheimer, Parkinson or Huntington, and paves the way for real-world implementation of precision medicine.

I completed my BS and MS (Pharm.) in India. Before joining Oxford in Nov 2019, I worked as a research assistant at the Central Drug Research Institute, in India. The focus of my DPhil centres around studying the role of BDNF-TRKB signalling in the initiation process of motor dysfunction and early degenerative changes in a transgenic mouse model with a selective deletion of Trkb from the striatopallidal enkephalinergic medium spiny neurons. This includes studying the impact of the dysregulation of a newly identified key candidate gene on the increased vulnerability of striatal neurons to degeneration. My DPhil is supported by Commonwealth Secretariat UK Fellowship (2019-22). My poster number is #P1038 / #2775, please feel free to send me an email (yaseen.malik@pharm.ox.ac.uk) if you happen to see it and have any questions or suggestions.

I am consultant working in community memory services in Teesside

Anna Mallach is a Postdoctoral Research Fellow in the de Strooper/ Arancibia lab at the UK Dementia Research Institute based at University College London. She is exploring changes in cellular interactions around Alzheimer’s pathology in animal models and human post-mortem brain tissue using state-of-the-art spatial transcriptomic techniques.

Maura Malpetti is a Race Against Dementia and Alzheimer's Research UK Fellow at the University of Cambridge (UK), where she earned her PhD in Clinical Neurosciences. She originally trained in Italy, where she worked with FDG PET. She is interested in the study of neuropathology, biomarkers and clinical features of neurodegenerative diseases, with special interest in frontotemporal lobar degeneration and Alzheimer's disease. Her research focusses on multimodal biomarkers to investigate the pathophysiology of these diseases, in order to identify early diagnostic and prognostic markers. Specifically, she is studying novel clinically viable PET tracers and other biomarkers for inflammation, tau and synaptic loss, with an interdisciplinary approach that integrates multimodal imaging and clinical data with fluid markers and post-mortem pathology.

I received a BS/MS degree in Chemistry (with a biophysical chemistry focus) from Philadelphia's Drexel University in 2017 before moving onto the Medical Scientist Training Program at the Ohio State University. At Drexel, my research focused on conformational dynamics of cytochrome c during the early stages of apoptosis, which I probed with various biochemical and spectroscopic techniques. At the Ohio State University, I have joined the lab of Dr. Jeff Kuret where we focusing on tau protein in the context of Alzheimer's disease and other tauopathies. I currently apply structural biology, biochemistry, and molecular biology techniques to study the formation of tau amyloids in vitro.